Hepatic and metabolic effects
reductions in liver steatosis
Patients treated with pegozafermin for 8 weeks had significant reductions in liver steatosis compared with placebo (LS mean percent change −42.2% versus −8.3%; 95% CI: −60.9%, −8.7%; 